

**Title:** Collaborative Approaches to the Treatment of Chronic Myelogenous Leukemia: An Interactive Grand Rounds Series

**Dates:** Live activities held February 24, 2016, March 24, 2016, March 30, 2016, April 5, 2016, April 19, 2016, April 29, 2016, May 20, 2016, June 1, 2016, and June 16, 2016

**Locations:** Alexandria, VA; Lawrenceville, GA; Ventura, CA; Pittsburgh, PA; West Palm Beach, FL; Washington, DC; Shreveport, LA; and Chicago, IL

## **Learning Objectives**

*At the conclusion of this activity, participants should be better able to:*

- Differentiate among the safety, tolerability, and clinical outcomes of available BCR-ABL tyrosine kinase inhibitors for the first- and second-line treatment of chronic myelogenous leukemia (CML)
- Identify treatment response criteria and implement consensus response monitoring and cytogenetic/molecular testing guidelines
- Evaluate the latest clinical data on the treatment of resistant disease in the third-line setting and beyond
- Identify, prevent, and manage drug and disease related side effects to minimize treatment modifications and discontinuations
- Explain best practices for engaging patients with CML to make more informed treatment decisions and improve adherence to oral therapy

## **Target Audience**

This activity is designed for medical oncologists, hematologists, oncology nurses, and other healthcare professionals involved in the care and treatment of patients who have chronic myelogenous leukemia.

## **Program Overview**

The activity will address remaining questions regarding the optimal sequencing of first-, second-, and third-generation TKIs at various points in the disease course; treatment guidelines regarding accurate and regular response monitoring and mutational testing; and patient education on management of disease and side effects to maximize adherence to oral TKI therapy. This activity will include any relevant data updates from the American Society of Hematology (ASH) Annual Meeting in December 2015.

## **Faculty**

Michael W.N. Deininger, MD, PhD (Chair)  
Professor and Chief of Hematology and Hematologic Malignancies  
Adjunct Professor, Department of Oncological Sciences  
Senior Director of Transdisciplinary Research  
Huntsman Cancer Institute at the University of Utah  
Salt Lake City

## **Physician Continuing Medical Education**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and AXIS Medical Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

## **Physician Credit Designation Statement**

Clinical and Patient Educators Association designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# CLINICAL & PATIENT EDUCATORS ASSOCIATION

## **Disclosure of Conflicts of Interest**

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

## **Commercial Support**

This activity is supported by an educational grant from Novartis Pharmaceuticals.